A
Alcista
Alcista · 25%BNTC
$11.85
Precio del escenario
$9.280
+0.973 (+10.48%)Al cierre
Loading chart…
- Máximo
- 9.390
- Apertura
- 8.670
- Precio medio ponderado por volumen
- 9.11
- Volumen
- 298.14K
- Capitalización
- 66.04M
- Mínimo
- 8.670
- Importe
- 2.72M
- EV/EBITDA, TTM
- 0.00
Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
Análisis de IA of Benitec Biopharma Inc (BNTC)
MantenerBenitec Biopharma Inc (BNTC) is not a good buy right now due to its current price of $8.49, which is significantly below its 52-week high of $15.86, indicating a 46.5% potential upside if it reaches that level. However, the stock has a low RSI of 39.12, suggesting it is nearing oversold conditions, but the forward P/E ratio is 0, indicating no expected earnings in the near term. The company also reported a net loss of $12.81 million in the latest quarter, raising concerns about its financial stability.
Recomendaciones de analistas (1)
+244.83% de potencial alcista
Mantener
0 Comprar
1 Mantener
0 Vender
Actual: 9.28
Mínimo
32.00
Promedio
32.00
Máximo
32.00
Wedbush
Superar al mercado
$17
2026-09-15
Wedbush
2026-09-15
Precio objetivo
$17
Superar al mercado
Wedbush
Superar al mercado
$16
2026-07-28
Wedbush
2026-07-28
Precio objetivo
$16
Superar al mercado
Evercore ISI
Superar al mercado
$25
2026-05-12
Evercore ISI
2026-05-12
Precio objetivo
$25
Superar al mercado
H.C. Wainwright
Comprar
$32
2025-11-24
H.C. Wainwright
2025-11-24
Precio objetivo
$32
Comprar
H.C. Wainwright
Comprar
$35
2025-11-04
H.C. Wainwright
2025-11-04
Precio objetivo
$35
Comprar
Métricas de valoración
El PER previsto actual de Benitec Biopharma Inc (BNTC) es 0.00, frente a su media de 5 años de -3.48.
Escenarios de precio de Alphio AI para BNTC
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con BNTC en cartera
Cronología de eventos
Noticias
9.509-15NASDAQ.COMBenitec Biopharma Reports FY 2026 Financial Results and Clinical Updates
9.505-14seekingalphaBenitec Q3 Earnings Beat Expectations
6.005-12CNBCLatest Wall Street Ratings Overview
5.004-27NewsfilterSeaport Therapeutics Appoints Dr. Sharon Mates to Board of Directors
- 8.503-10Newsfilter
Benitec Biopharma Showcases BB-301 Clinical Results at MDA Conference
Preguntas frecuentes sobre BNTC, respondidas por Alphio AI
Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Benitec Biopharma Inc (BNTC) is not a good buy right now due to its current price of $8.49, which is significantly below its 52-week high of $15.86, indicating a 46.5% potential upside if it reaches that level. However, the stock has a low RSI of 39.12, suggesting it is nearing oversold conditions, but the forward P/E ratio is 0, indicating no expected earnings in the near term. The company also reported a net loss of $12.81 million in the latest quarter, raising concerns about its financial stability.
1 analysts cover BNTC: 0 rate it Buy, 1 Hold and 0 Sell. The average price target is 32.00.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
- AppLovin Q3 2026 Deep Dive: Beaten-Down S&P Dog Meets Axon Next-Gen Beat-and-Raise—and a $3.2B BuybaAppLovin Q3 2026: $2.185B rev (+55%), EPS $4.30 vs ~$4.03–4.04 Street, Adj EBITDA $1.842B (84%). Beat own guide $100M; Q4 $2.365–2.395B; auth +$3.2B; AH +22–24%.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.